Tyrosine Kinase Inhibitor STI571 in the Treatment of Philadelphia Chromosome-Positive Leukaemia Failing Myeloablative Stem Cell Transplantation
Bone marrow transplantation(2002)
Abstract
Eight patients with Philadelphia chromosome-positive (Ph+) leukaemia relapsing from stem cell transplantation (SCT) (one syngeneic and seven allogeneic) were treated with the tyrosine kinase inhibitor STI571. Five patients relapsing as chronic myeloid leukaemia (CML) in chronic phase achieved a complete haematological response, with complete and major cytogenetic responses occurring in four and one cases, respectively. One patient became negative for BCR/ABL in the bone marrow. Three patients relapsed as acute leukaemia (two CML in myeloblastic crisis and one Ph+ acute lymphoblastic leukaemia), all of whom achieved haematological and cytogenetic responses. One patient also became BCR/ABL negative. However, pancytopenia and graft-versus-host disease led to cessation of treatment in the remaining two cases, which was followed by disease recurrence refractory to further STI treatment. Our results showed that Ph+ leukaemic relapses after SCT might respond well to STI571 therapy.
MoreTranslated text
Key words
Ph,leukaemia relapse,stem cell transplantation,STI571
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined